Literature DB >> 18394761

[C-reactive protein (CRP) after revascularized STEMI: is CRP a prognostic factor?].

F Roubille1, G Cayla, M-C Picot, V Pradet, F Massin, R Gervasoni, J-L Pasquie, J-C Macia, C Piot, F Leclercq.   

Abstract

PURPOSE: During myocardial infarction (MI), numerous biomarkers increase, such as troponin (necrosis), BNP, and high sensibility C-reactive protein (hsCRP) (inflammation). The objectives of the study were to study kinetics of hsCRP after a revascularized MI, and correlations between hsCRP and clinical outcomes or biological markers, and prognostic value of CRP. PATIENTS AND METHODS: Fifty-two patients were admitted for STEMI (ST segment Elevation MI). Primary coronarography interventions (PCI) were performed for urgent reperfusion. Patients were included only in case of success (TIMI 3). Clinical examination was completed by a biological follow-up of BNP, troponin-I (before and after PCI, days 1, 2, 3, 6) and hsCRP (days 0, 1, 2, 3, 6). Clinical outcomes follow-up was performed during hospitalization, on the first month, and the sixth month.
RESULTS: hsCRP increases during the first days (peak on day 3: 46.1mg/L), and decreases between the third and the seventh day. Clinical outcomes were correlated with CRP: door-to-balloon time, age, creatinin level on admission. During follow-up, there were clinical events in 13/49 (26%) of the patients. Among them, hsCRP on day 2 was higher (p < 0.0001), compared to other patients. Compared to other biological markers, hsCRP was correlated with BNP on days 2 and 3 (p = 0.008).
CONCLUSION: hsCRP increases after revascularized STEMI, in accordance to the infarct size, in the first days. hsCRP is correlated with cardiovascular pronostic biomarkers. hsCRP could play an active role, and could be used as a pronostic biomarker after revascularized STEMI, which are usually considered as a low-risk population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18394761     DOI: 10.1016/j.revmed.2008.01.026

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  6 in total

1.  Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis.

Authors:  Christian Lunetta; Andrea Lizio; Eleonora Maestri; Valeria Ada Sansone; Gabriele Mora; Robert G Miller; Stanley H Appel; Adriano Chiò
Journal:  JAMA Neurol       Date:  2017-06-01       Impact factor: 18.302

2.  Shenfu Injection () inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock.

Authors:  Yan-Yan Jin; Hai Gao; Xin-Yong Zhang; Hui Ai; Xiao-Lin Zhu; Jing Wang
Journal:  Chin J Integr Med       Date:  2016-12-27       Impact factor: 1.978

3.  Oxidized Low Density Lipoprotein and High Sensitive C-Reactive Protein in Non-Diabetic, Pre-Diabetic and Diabetic Patients in the Acute Phase of the First Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention.

Authors:  Danijela Trifunović; Sanja Stanković; Jelena Marinković; Marko Banović; Nina Đukanović; Olga Vasović; Bosiljka Vujisić-Tešić; Milan Petrović; Jelena Stepanović; Ana Đorđević-Dikić; Branko Beleslin; Ivana Nedeljković; Milorad Tešić; Miodrag Ostojić
Journal:  J Med Biochem       Date:  2015-03-03       Impact factor: 3.402

4.  Efficacy and safety of colchicine in the treatment of acute myocardial infarction: A protocol for systematic review and meta-analysis.

Authors:  Hui Xiong; Xianli Huang; Lingzhang Rao; Jinhe Zhao
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

Review 5.  Therapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury.

Authors:  Carlota Fernandez Rico; Karidia Konate; Emilie Josse; Joël Nargeot; Stéphanie Barrère-Lemaire; Prisca Boisguérin
Journal:  Front Cardiovasc Med       Date:  2022-02-17

6.  Effect of Treatment with Colchicine after Acute Coronary Syndrome on Major Cardiovascular Events: A Systematic Review and Meta-Analysis of Clinical Trials.

Authors:  Erfan Razavi; Akam Ramezani; Asma Kazemi; Armin Attar
Journal:  Cardiovasc Ther       Date:  2022-04-13       Impact factor: 3.368

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.